Horizon Biotechnology Co., Ltd. (6986) is successfully establishing a robust operational model through its dual strategy of developing allogeneic mesenchymal stem cell therapies and providing CMO/CDMO services. Recently, the company changed its lead advisory broker to Taishin Securities, aiming to submit an OTC listing application by the end of this year. Taishin Securities has a strong background in guiding the biotech industry, and they are optimistic about Horizon's growth potential in regenerative medicine and CDMO, leveraging their expertise to help integrate capital market resources to accelerate growth.

Currently, Horizon focuses on the development of stem cell therapies for cardiovascular and degenerative diseases, equipped with nine automated production lines that highlight its leading position in Taiwan's biotech sector. Forecasts for 2024 suggest revenues of NT$286 million, a year-on-year increase of 119.36%, and a net profit of NT$147 million, representing a 339.62% increase. In the next five years, the global regenerative medicine market is expected to continue its growth trend, and Horizon is poised to seize this opportunity to enhance its market leadership.